Orris

My nmosd patient was treated with rituximab for which she developed leukopenia and thrombocytopenia and she develepoed dvt platelet count -76000 how should we start enoxaparin

Reading File
Reading File
Searching the Web

thrombocytopenia acute venous thromboembolism platelet 50,000 full dose LMWH guideline

Searching PubMed

venous thromboembolism thrombocytopenia anticoagulation

Finding Sources
Reading Web Page

https://pmc.ncbi.nlm.nih.gov/articles/PMC6596377

With an acute, objectively confirmed DVT and platelets 76,000/µL, therapeutic anticoagulation is generally appropriate if there is no active major bleeding, rapidly falling platelet count, or another contraindication.
Practical approach
  • Enoxaparin 1 mg/kg subcutaneously every 12 hours is a reasonable initial therapeutic regimen. Twice-daily dosing is usually preferable here because it can be adjusted or held more readily if platelets fall.
  • If CrCl <30 mL/min, use 1 mg/kg once daily or consider IV unfractionated heparin if close titration and rapid reversal may be needed.
  • Do not use a fixed prophylactic dose for a clinically important acute proximal DVT simply because the platelet count is 76,000/µL.
The commonly used platelet-based approach is:
  • ≥50,000/µL: full-dose LMWH
  • 30,000 to 50,000/µL: consider 50% therapeutic LMWH, or if the DVT is high-risk or very recent, platelet transfusion support to maintain roughly 40,000 to 50,000/µL while providing full-dose anticoagulation
  • <25,000 to 30,000/µL: generally hold therapeutic anticoagulation temporarily and individualize urgently with hematology, considering transfusion support and, only in selected cases where anticoagulation cannot be given, a temporary IVC filter. This threshold framework is supported by an expert LMWH consensus and summarized in a recent thrombocytopenia anticoagulation review.
Before and during the first dose
  1. Confirm platelet count on a repeat CBC, preferably also exclude EDTA clumping with a smear or citrate sample if unexpected.
  2. Assess for bleeding: melena, hematuria, menorrhagia, mucosal bleeding, intracranial symptoms.
  3. Check creatinine/eGFR, hemoglobin trend, PT/INR, aPTT, liver function, fibrinogen if DIC is possible.
  4. Clarify whether she had any heparin exposure in the prior 5 to 100 days. If yes, calculate a 4Ts score and send PF4/heparin testing if indicated. If HIT is plausible, do not start enoxaparin. Use a non-heparin anticoagulant under hematology guidance.
  5. Monitor CBC/platelets daily initially. If platelets decline toward <50,000/µL, reassess dose and cause.
Rituximab can cause delayed cytopenias, but a DVT plus thrombocytopenia warrants evaluation beyond attributing it solely to rituximab: infection, marrow suppression, immune thrombocytopenia, consumptive coagulopathy, antiphospholipid syndrome, occult malignancy, and heparin exposure should be considered. In an NMOSD patient, also check whether other agents, recent plasma exchange, infection, or systemic autoimmune disease are contributing.
For the information supplied, I would favor starting enoxaparin 1 mg/kg SC q12h now, with close platelet surveillance and hematology involvement, assuming normal renal function, no active bleeding, and no concern for HIT.

Can rituximabcause leukopenia and thrombocytopenia

Reading File
Finding Sources
Searching the Web

rituximab prescribing information leukopenia thrombocytopenia late-onset neutropenia

Searching PubMed

rituximab late onset neutropenia thrombocytopenia

Yes. Rituximab can cause leukopenia, especially neutropenia, including a delayed syndrome called late-onset neutropenia, typically occurring 4 weeks or more after the last dose and sometimes several months later. It may resolve spontaneously but can cause serious infection if severe. The reported timing is often 38 to 175 days after exposure in autoimmune and hematologic settings, as summarized in this rituximab safety review.
Thrombocytopenia can also occur, but is less typical in NMOSD patients receiving rituximab alone than neutropenia. It can be:
  • Acute, occasionally within days of infusion
  • Delayed or immune-mediated
  • Due to an associated cause rather than rituximab itself, such as infection, autoimmune cytopenia, marrow disease, concomitant drugs, hypersplenism, DIC/TMA, or nutritional deficiency
The FDA label reports cytopenias with rituximab, including leukopenia and thrombocytopenia, though rates vary greatly by indication and are much higher when combined with cytotoxic chemotherapy. See the FDA prescribing information.
For your patient with both leukopenia and platelets 76,000/µL plus DVT, do not assume all abnormalities are from rituximab. I would evaluate:
  • CBC with differential and peripheral smear, including repeat count to exclude platelet clumping
  • Timing of all rituximab doses and other drugs
  • Infection screen as clinically indicated
  • Hemolysis/TMA screen: LDH, bilirubin, haptoglobin, reticulocytes, smear for schistocytes, creatinine
  • Coagulation testing and fibrinogen if consumption/DIC is possible
  • Autoimmune cytopenia assessment where appropriate
  • Bone marrow evaluation if persistent, progressive, unexplained, or involving multiple cell lines
If ANC is markedly low or fever develops, treat it as urgent possible neutropenic infection. Further rituximab should generally be deferred while significant unexplained cytopenias are evaluated.
This is a shared conversation. Sign in to Orris to start your own chat.